Blood Pressure: PRIMED Legacy Harmonization
These are the algorithms for the PRIMED Harmonized systolic and diastolic blood pressures (SBP and DBP). The overall procedure of gathering single BP values per individual consists of:
Owner Phenotyping Groups:
View Phenotyping Groups:
Final
Body Mass Index (BMI): PRIMED Legacy Harmonization
These are the PRIMED Harmonization instructions for body mass index (BMI).
Overall procedure
1. Extract trait measurements using measurement codes and calculations
2. Convert measurement units to expected units, if necessary
3. Apply measurement exclusion criteria, other than statistical outliers
4. Remove statistical outliers
5. Compute a single value per individual for inclusion in analysis
6. Calculate counts of flagged individuals
Owner Phenotyping Groups:
View Phenotyping Groups:
Final
Breast Cancer: PRIMED General Harmonization
These are the PRIMED General Harmonization instructions for breast cancer (BC). We are using the breast cancer definition used by the eMERGE program, with some additional data types included. These instructions expand to include data structures from cohort, EHR, biobank, and OMOP structured data as these vary across studies and available data.
Please see Breast Cancer: PRIMED Legacy Harmonization for a more narrowed down definition for implementation.
Owner Phenotyping Groups:
View Phenotyping Groups:
Final
Breast Cancer: PRIMED Legacy Harmonization
These are the PRIMED Harmonization instructions for breast cancer (BC) derived for the PRIMED Legacy Project. These instructions are more detailed and narrowed than the general instructions for direct use in analysis. We are using the breast cancer definition used by the eMERGE program, with some slight modifications. Follow this document for implementation.
Modifications:
We will only include cis females in the analyses
Owner Phenotyping Groups:
View Phenotyping Groups:
Final
Computable Phenotypes for Identifying Patients with Lung and Gastroenteropancreatic Neuroendocrine Tumors in PCORnet
This phenotype specification supports the identification of patients with lung and gastroenteropancreatic (GEP) neuroendocrine tumors (NETs) for the Neuroendocrine Tumors- Patient-Reported Outcomes Study (NET-PRO) - a multi-site, patient-centered outcomes research initiative (PCORI) funded study (RD-2020C2-20329) conducted within PCORnet.
Owner Phenotyping Groups:
View Phenotyping Groups:
Final
Coronary Heart Disease (CHD): PRIMED General Harmonization
These are the PRIMED General Harmonization instructions for coronary artery disease (CAD) also known as coronary heart disease (CHD). We are using the CHD definition used by the eMERGE program, with some additional data types included. These instructions expand to include data structures from cohort, EHR, biobank, and OMOP structured data as these vary across studies and available data.
Please see Coronary Heart Disease (CHD): PRIMED Legacy Harmonization for a more narrowed down definition for implementation.
Files Included:
Owner Phenotyping Groups:
View Phenotyping Groups:
Final
Coronary Heart Disease (CHD): PRIMED Legacy Harmonization
Algorithm for coronary heart disease (aka coronary artery disease) based on research done by the eMERGE Network. Cases are ascertained by either two ocurrences of diagnostic codes or one ocurrence of a procedural code. Defined as individuals with no diagnostic or procedural codes recorded. All ICD-9 and ICD-10 codes are labeled as diagnostic or procedural in the attached excel file.
Owner Phenotyping Groups:
View Phenotyping Groups:
Final
Febrile Neutropenia (Pediatric)
Background: Febrile neutropenia (FN) is a serious complication of myelosuppressive chemotherapy, defined by fever occurring in the context of neutropenia. Prompt recognition and treatment are essential to reduce morbidity and mortality. This algorithm focuses on "high-risk" FN as defined in the ‘Early versus Late Stopping of Antibiotics in high-risk FN’ (ELSA-FN) randomised control trial as expected absolute neutrophil count (ANC) <500 cells/mm3 for ≥7 days.
Owner Phenotyping Groups:
View Phenotyping Groups:
Final